Sanofi SEC Filings

Sanofi reported two July 2026 updates. One outlines an evolution of the Executive Committee effective September 1, 2026, with leadership changes across regional roles and global functions. Madeleine Roach will become President and Country Lead for Germany, Switzerland and Austria, with her current business operations responsibilities folded into Finance, whose remit will expand to include Global Partnering and Business Development. Thomas Triomphe will add responsibility for China alongside Vaccines leadership, while Olivier Charmeil moves to Strategic Projects Advisor to the CEO and Roy Papatheodorou, Executive Vice President and General Counsel, will leave after over four years.

The other update announces discontinuation of clinical development of amlitelimab in moderate-to-severe atopic dermatitis and a decision not to submit the drug for global regulatory reviews, after determining that the totality of efficacy and safety evidence would not deliver a meaningful improvement over current standard of care. Ongoing atopic dermatitis studies will be wound down with patient transition plans, but a phase 2 study of amlitelimab in celiac disease continues, with results expected in the second half of 2026. Sanofi is not changing its full-year 2026 guidance following this decision.

Amundi and its subsidiary Amundi Asset Management report beneficial ownership of 68,651,904 Sanofi common shares, representing 5.65% of the class. They report no sole voting or dispositive power, but shared voting power over 36,655,093 shares and shared dispositive power over the full 68,651,904 shares.

Within this position, 28,906,920 shares are held through a French employee investment vehicle (FCPE) dedicated to Sanofi employees. Voting rights for these FCPE shares are exercised by the FCPE’s supervisory board, where employee representatives hold the majority, and not by Amundi.

Sanofi reports that the US FDA has approved subcutaneous Sarclisa Escena (isatuximab-irfc) for multiple myeloma in combination with standard regimens across all existing Sarclisa IV indications. Sarclisa Escena becomes the first anticancer treatment administered via an on-body injector or manual subcutaneous injection.

The pivotal IRAKLIA phase 3 non-inferiority study showed Sarclisa Escena delivered by on-body injector achieved a 71.1% objective response rate versus 70.5% with IV Sarclisa, with a similar overall safety profile but markedly fewer systemic administration reactions, 1.5% versus 25%. Injection site reactions occurred in 0.4% of 5,145 on-body injections, nearly all mild. Sarclisa Escena is given as a fixed 1,400 mg subcutaneous dose and Sarclisa-based regimens have treated more than 70,000 patients worldwide, with approvals in almost 60 countries across several multiple myeloma indications.

Sanofi reported positive phase 3 results from its Baby-COMET study of Nexviazyme (avalglucosidase alfa) in infants with infantile-onset Pompe disease (IOPD). The trial met its primary endpoint, with treatment-naïve participants six months and younger alive and free of invasive ventilation at 52 weeks of treatment.

The study also met all secondary endpoints, including ventilator-free survival at 12 and 18 months of age and numerical improvements in cardiac and motor function measures at 52 weeks. Nexviazyme was well tolerated, with no serious treatment-related adverse events and manageable infusion reactions. The data will support a planned U.S. regulatory submission for a label extension in the second half of 2026.

Sanofi filed a Form 6-K summarizing several June 2026 milestones. Japan approved a subcutaneous formulation of Sarclisa for multiple myeloma, including use with standard regimens and potential future administration via an on-body injector, supported by the phase 3 IRAKLIA study showing non-inferior efficacy versus intravenous dosing.

The European Commission approved Cenrifki for adults with secondary progressive multiple sclerosis without recent relapses, based on the HERCULES and GEMINI phase 3 programs, with drug-induced liver injury identified as a key safety risk requiring liver monitoring. Japan also authorized Wayrilz for persistent or chronic immune thrombocytopenia after the LUNA 3 phase 3 study met primary and secondary endpoints.

Separately, Sanofi appointed Paulo Fontoura as Executive Vice President and Global Head of R&D Pharma, effective September 1, 2026, adding an experienced R&D leader to its executive committee.

Sanofi reports that the US FDA has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline of natural insulin production in children aged eight to 17 years recently diagnosed with stage 3 type 1 diabetes. This makes Tzield the first disease-modifying therapy for autoimmune type 1 diabetes in this setting.

The decision is based on the phase 3 PROTECT study, where Tzield significantly slowed the decrease in C-peptide, a marker of beta cell function, compared with placebo, and on data from more than 900 treated patients. Approval is conditional on confirmation of clinical benefit in the ongoing BETA-PRESERVE phase 3 study.

Sanofi filed a Form 6-K highlighting three June 2026 updates. It launched its Action 2026 global employee share plan, offering up to 9,816,701 new shares at a €59.87 subscription price, a 20% discount, plus one free matching share for every five purchased, within individual and legal limits.

Sanofi also received European Commission approval for subcutaneous Sarclisa in multiple myeloma, including delivery via the CirCLIQ on-body injector, supported by phase 3 data showing non-inferior efficacy and fewer systemic infusion reactions versus intravenous use. Separately, Sanofi will stop the riliprubart MOBILIZE phase 3 CIDP study after an interim analysis found it unlikely to show sufficient efficacy, though no safety signals were identified and 2026 financial guidance remains unchanged.

Sanofi reports that the US FDA has granted priority review to its new drug application for venglustat, an oral glucosylceramide synthase inhibitor, to treat type 3 Gaucher disease, a rare lysosomal storage disorder with neurological symptoms. If approved, venglustat would be the first US therapy aimed at the progressive neurological manifestations of this disease. The FDA’s target action date is November 25, 2026.

The application is backed by the phase 3 LEAP2MONO study in adults and adolescents with stabilized systemic disease on enzyme replacement therapy. Venglustat met both primary neurological endpoints and three of four key secondary endpoints and was generally well tolerated, with no new safety signals.

Sanofi reported phase 2 ElevAATe data showing its investigational AATD therapy efdoralprin alfa outperformed standard plasma-derived augmentation in raising and sustaining functional alpha-1 antitrypsin (fAAT) levels in adults with AATD-related emphysema.

Efdoralprin alfa given every three weeks achieved mean fAAT trough increases more than three times higher than weekly plasma-derived protein and met the primary endpoint with strong statistical significance (p<0.0001). All key secondary endpoints were also met. In the three‑week dosing arm, fAAT remained above the normal threshold of 23.8 µM for 100% of days over the 32‑week study versus 41% of days on standard therapy.

The safety profile was comparable to current treatment, with no treatment-emergent adverse events leading to permanent discontinuation and similar rates of common side effects such as COPD exacerbations, headache and COVID‑19 infection. Efdoralprin alfa has fast track and orphan drug designations in the US and orphan designation in the EU and remains in clinical development with ongoing long-term evaluation.